30.05.2022 Views

Data integrity PIC S

good practices for data management and integrity in regulatory GMP/GDP environments

good practices for data management and integrity in regulatory GMP/GDP environments

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Quality monitoring

Quality and performance monitoring may indicate incentive

for data falsification (e.g. raw materials which marginally

comply with specification on a frequent basis.

10.3.5 Contract givers may work with the contract acceptor to ensure that all clientconfidential

information is encoded to de-identify clients. This would facilitate

review of source electronic data and metadata at the contract giver’s site,

without breaking confidentiality obligations to other clients. By reviewing a

larger data set, this enables a more robust assessment of the contract

acceptors data governance measures. It also permits a search for indicators

of data integrity failure, such as repeated data sets or data which does not

demonstrate the expected variability.

10.3.6 Care should be taken to ensure the authenticity and accuracy of supplied

documentation (refer section 8.11). The difference in data integrity and

traceability risks between ‘true copy’ and ‘summary report’ data should be

considered when making contractor and supply chain qualification decisions.

11 REGULATORY ACTIONS IN RESPONSE TO DATA INTEGRITY

FINDINGS

11.1 Deficiency references

11.1.1 The integrity of data is fundamental to good manufacturing practice and the

requirements for good data management are embedded in the current PIC/S

Guides to GMP/GDP for Medicinal products. The following table provides a

reference point highlighting some of these existing requirements.

ALCOA principle

Attributable

PIC/S Guide

to Good

Manufacturing

Practice for

Medicinal

products,

PE 009

(Part I):

[4.20, c & f],

[4.21, c & i],

[4.29 point 5]

Legible [4.1], [4.2],

[4.7], [4.8],

[4.9], [4.10]

PIC/S Guide

to Good

Manufacturing

Practice for

Medicinal

products,

PE 009

(Part II):

[5.43], [6.14],

[6.18], [6.52]

[6.11], [6.14],

[6.15], [6.50]

Annex 11

(Computerised

Systems)

[2], [12.1],

[12.4], [15]

[4.8], [7.1], [7.2]

[8.1], [9], [10],

[17]

PIC/S

Guide to

Good

Distribution

Practice for

Medicinal

products,

PE 011:

[4.2.4],

[4.2.5]

[4.2.3],

[4.2.9]

Contemporaneous [4.8] [6.14] [12.4], [14] [4.1], [4.2.9]

Original [4.9], [4.27],

[Paragraph

"Record"]

[6.14], [6.15],

[6.16]

[8.2], [9] [4.2.5]

PI 041-1 56 of 63 1 July 2021

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!